ST Pharm Co.,Ltd. Announces Expansion of Oligonucleotide Facility
November 29, 2021 at 05:30 pm IST
Share
ST Pharm Co. Ltd. announced to build the second oligonucleotide manufacturing plant for an expansion of production facilities and to preoccupy the rapidly growing oligonucleotide therapeutics market. ST Pharm will invest in total $126 million at Banwol campus located in Ansan until 2025 and this will construct the second oligonucleotide plant with four to six large production lines. The second oligonucleotide manufacturing plant will be designed to maximise efficiency by shortening the production period through a parallel cross-production process design. In addition, ST Pharm will be installing a solvent recycling system for cost reduction and to make eco-friendly manufacturing process. Furthermore, the establishment of the second oligonucleotide plant will provide a production capacity of 14 mole per year, which forecasts ST Pharm to become the world's large leading CDMO in oligonucleotide production in 2025, in terms of capacity.
STPharm Co.,Ltd. is a Korea-based company principally engaged in manufacture of pharmaceutical products. The Company's products mainly consist of generic active pharmaceutical ingredients (APIs), such as tipepidine hibenzate, doxifluridine, clopidogrel bisulfate, voriconazole and new medicine APIs, such as small molecule APIs. The Company distributes its products within domestic market and to overseas markets.